<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02788786</url>
  </required_header>
  <id_info>
    <org_study_id>OPP1131701</org_study_id>
    <nct_id>NCT02788786</nct_id>
  </id_info>
  <brief_title>Feasibility and Acceptability of Use of Daily Oral Rinse in Pregnant Women in Rural Nepal</brief_title>
  <official_title>Feasibility and Acceptability of Daily Oral Rinse in Pregnant Women and Impact on Oral Inflammatory Biomarkers in Rural Nepal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Nepal, investigators are conducting a cohort study to estimate the relationship between&#xD;
      signs of periodontal disease in pregnant women and preterm delivery. Within that cohort&#xD;
      study, investigators plan to conduct an individually randomized trial of the acceptability&#xD;
      and effect chlorhexidine, cetylpyridinium chloride, and salt water oral rinses on gingival&#xD;
      crevicular fluid and plaque during pregnancy. Women for this pilot trial will be chosen from&#xD;
      a subset of the area currently engaged in the larger cohort study, to simplify logistics. The&#xD;
      pilot trial will have four arms (three oral rinse arms, and one control group).&#xD;
&#xD;
        -  Arm 1: Twice daily oral rinse containing chlorhexidine 0.12% w/v (n=25 women with&#xD;
           periodontitis&#xD;
&#xD;
        -  Arm 2: Twice daily oral rinse with cetylpyridinium chloride (n=50; 25 women with/without&#xD;
           periodontitis)&#xD;
&#xD;
        -  Arm 3: Twice daily oral rinse with salt and water (n=50: 25 women with/without&#xD;
           periodontitis)&#xD;
&#xD;
        -  Arm 4: No oral rinse (n=50)&#xD;
&#xD;
      To select and enroll these 175 participants, data collectors will use the information they&#xD;
      collected during an oral health clinical examination conducted at the time of enrollment into&#xD;
      the broader cohort study; this information will be used to classify women by signs of&#xD;
      periodontitis.&#xD;
&#xD;
      Those selected through this above process will be read an additional consent form; those&#xD;
      agreeing to participate will be provided with a supply of their assigned rinse (and&#xD;
      instructions on its use and handling/storage), or no rinse. Those in the three rinse groups&#xD;
      will be asked to use the provided rinse twice per day after brushing and to save the empty&#xD;
      bottles for collection by the health care worker. At the end of this first visit, women will&#xD;
      additionally provide a venous blood sample to measure systemic inflammation markers and&#xD;
      fluoride.&#xD;
&#xD;
      Women receiving the rinse will be visited by study workers periodically to provide more oral&#xD;
      rinse and check on their adherence to the rinse. All 175 women will be visited after 12 weeks&#xD;
      to undergo a second oral health clinical examination and provide a second set of gingival&#xD;
      crevicular fluid and plaque samples, to allow for evaluation of the effect of each of the&#xD;
      oral rinses as compared to the normal physiological changes in gingival inflammation and&#xD;
      biofilm composition during the course of pregnancy.&#xD;
&#xD;
      At this final visit, the women in the three rinse arms will also answer a short questionnaire&#xD;
      to gather feedback on acceptability and adherence to the oral rinse.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2016</start_date>
  <completion_date type="Actual">November 15, 2016</completion_date>
  <primary_completion_date type="Actual">November 15, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Do women accept the use of their assigned oral rinse?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in gingival crevicular fluid (IL-1β, IL-6, IL-10, TNF-α, PGE2, and GM-CSF)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Do the oral rinses (or no rinse) have differing impacts on inflammatory markers in gingival crevicular fluid. Specifically, IL-1β, IL-6, IL-10, TNF-α, PGE2, and GM-CSF will be measured (pg/ml) using validated multiplex immunoassays.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Periodontitis</condition>
  <condition>Premature Birth of Newborn</condition>
  <arm_group>
    <arm_group_label>chlorhexidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.12% w/v chlorhexidine oral rinse; 15ml, twice-daily, for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cetylpyridinium chloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-alcoholic cetylpyridinium chloride oral rinse; 15ml, twice-daily, for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salt and Water</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salt and water based oral rinse; 15ml, twice-daily, for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No oral rinse</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No rinse provided in this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine</intervention_name>
    <description>non-alcoholic chlorhexidine gluconate antiseptic mouth rinse</description>
    <arm_group_label>chlorhexidine</arm_group_label>
    <other_name>chlorhexidine oral rinse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetylpyridinium chloride</intervention_name>
    <description>non-alcoholic cetylpyridinium chloride antiseptic mouth rinse</description>
    <arm_group_label>cetylpyridinium chloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salt and Water</intervention_name>
    <description>salt and water mix oral rinse</description>
    <arm_group_label>Salt and Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  &lt;26 weeks gestation at enrollment&#xD;
&#xD;
          -  Enrolled in the broader cohort study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Already previously enrolled&#xD;
&#xD;
          -  Not Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luke C Mullany, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nepal Nutrition Intervention Project</name>
      <address>
        <city>Hariaun</city>
        <state>Sarlahi District</state>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chlorhexidine</keyword>
  <keyword>cetylpyridinium chloride</keyword>
  <keyword>gingival crevicular fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Cetylpyridinium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

